![]() | |
![]() Chemical structures of simnotrelvir (top) and ritonavir (bottom) | |
Combination of | |
---|---|
Simnotrelvir | SARS-CoV-2 3CLpro inhibitor |
Ritonavir | Protease inhibitor |
Clinical data | |
Trade names | 先诺欣 (Xiannuoxin) |
Pregnancy category |
|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Clinical data | |
---|---|
Other names | SIM0417, SSD8432 |
Routes of administration | Oral |
Drug class | SARS-CoV-2 3CLpro inhibitor |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 72.5% [1] |
Metabolism | hepatic (CYP3A) [1] |
Elimination half-life | 3.1 h; 4.1 h with ritonavir [1] |
Excretion | urine (55.4%), feces (36.7%) [1] |
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C22H30F3N5O4S2 |
Molar mass | 549.63 g·mol−1 |
3D model ( JSmol) | |
| |
|
Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. [2] Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, [3] a CYP3A inhibitor.
It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. [4] Results for the phase Ib trial are available. [5] In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo. [6]
![]() | |
![]() Chemical structures of simnotrelvir (top) and ritonavir (bottom) | |
Combination of | |
---|---|
Simnotrelvir | SARS-CoV-2 3CLpro inhibitor |
Ritonavir | Protease inhibitor |
Clinical data | |
Trade names | 先诺欣 (Xiannuoxin) |
Pregnancy category |
|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Clinical data | |
---|---|
Other names | SIM0417, SSD8432 |
Routes of administration | Oral |
Drug class | SARS-CoV-2 3CLpro inhibitor |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 72.5% [1] |
Metabolism | hepatic (CYP3A) [1] |
Elimination half-life | 3.1 h; 4.1 h with ritonavir [1] |
Excretion | urine (55.4%), feces (36.7%) [1] |
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C22H30F3N5O4S2 |
Molar mass | 549.63 g·mol−1 |
3D model ( JSmol) | |
| |
|
Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. [2] Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, [3] a CYP3A inhibitor.
It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. [4] Results for the phase Ib trial are available. [5] In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo. [6]